How to Fix Your Hormones Before Starting Treatment

FSH and LH: The Driving Forces of Follicular Development

Follicle stimulating hormone and luteinising hormone are produced by the pituitary gland and together orchestrate the monthly cycle of follicular development, ovulation, and luteal phase support. Measuring both on cycle day two or three provides a baseline snapshot of how the pituitary is functioning in relation to the ovaries.

Elevated FSH on cycle day two or three is one of the most significant indicators of declining ovarian reserve. As the follicle pool diminishes with age or for other reasons, the pituitary works harder to stimulate follicular development, producing more FSH. A day two or three FSH above 10 to 12 IU/L is generally considered elevated and indicates that ovarian reserve may be compromised. In the context of IVF, elevated FSH signals that a higher stimulation dose may be required and that the number of eggs retrieved per cycle may be lower than average.

LH elevation at baseline, particularly when accompanied by elevated androgens and irregular cycles, is a hallmark of PCOS. An elevated LH to FSH ratio is one of the diagnostic features of PCOS and reflects the altered hypothalamic-pituitary signalling pattern characteristic of the condition. In IVF, elevated LH can impair oocyte quality and the GnRH antagonist protocol is often used specifically to suppress premature LH surges in affected patients.

Estradiol: The Follicular Environment Hormone

Estradiol, the primary form of estrogen produced by developing follicles, is measured alongside FSH on cycle day two or three as part of the baseline assessment. Its role in this context is partly to validate the FSH measurement, as elevated estradiol can artificially suppress FSH through negative feedback and produce a falsely normal FSH reading in a woman with genuinely compromised ovarian reserve.

A day two or three estradiol above approximately 60 to 80 pg/mL when FSH is measured suggests that residual follicular activity from the previous cycle is suppressing FSH and that the FSH value may not accurately reflect the true baseline. Repeating the measurements in a subsequent cycle provides a more reliable picture.

During the stimulation phase of IVF, estradiol rises progressively as follicles develop and its trajectory provides essential information about ovarian response. A slow rise may indicate poor stimulation response. A rapid or excessive rise raises concern for OHSS in high-responder patients. Monitoring estradiol alongside follicle size allows the stimulation team to adjust protocol and trigger timing in real time.

Thyroid Hormones: The Reproductive System Regulator

Thyroid dysfunction is among the most common hormonal conditions affecting women of reproductive age and one of the most frequently missed in pre-IVF workups that rely only on TSH without the full thyroid panel.

As covered in detail in the thyroid and IVF guide earlier in this series, TSH levels above 2.5 mIU/L are associated with reduced IVF success rates, and thyroid autoantibodies impair implantation even in women with normal TSH. A complete pre-IVF thyroid assessment including TSH, free T4, and both anti-TPO and anti-thyroglobulin antibodies is essential, and identified abnormalities should be treated before the cycle begins.

Hypothyroidism is corrected with levothyroxine supplementation. Hyperthyroidism requires medical management in consultation with an endocrinologist before proceeding to IVF. Thyroid autoimmunity in women with normal TSH may be managed with low-dose levothyroxine supplementation based on individual clinical assessment and previous treatment history.

Prolactin: The Overlooked Fertility Disruptor

Elevated prolactin suppresses GnRH pulsatility, reduces FSH and LH secretion, impairs follicular development, and creates luteal phase insufficiency through reduced progesterone production. All of these effects directly impair IVF outcomes in women with unidentified hyperprolactinaemia.

Prolactin should be measured in a fasting morning blood sample taken at rest, as stress, exercise, and even the venepuncture itself can transiently elevate levels and produce a false positive result. A single mildly elevated result should always be confirmed with a repeat measurement before treatment is initiated.

When hyperprolactinaemia is confirmed, identifying its cause, whether prolactinoma, hypothyroidism, medication effect, or idiopathic, guides treatment. Dopamine agonist therapy with cabergoline or bromocriptine normalises prolactin in the majority of patients within weeks and significantly improves the hormonal environment for IVF stimulation.

Androgens: The PCOS Connection and Beyond

Androgens including testosterone and DHEAS are elevated in women with PCOS and contribute to the hormonal disruption that impairs follicular development, egg quality, and endometrial receptivity in this condition. Measuring testosterone and DHEAS as part of the pre-IVF hormonal workup identifies androgen excess that may require management before or during treatment.

In women with PCOS, insulin-sensitising therapy with metformin reduces androgen production by addressing the insulin resistance that drives it, and lifestyle interventions targeting weight and metabolic health produce similar benefits through the same pathway. In women with adrenal androgen excess contributing to elevated DHEAS, low-dose corticosteroid therapy may be appropriate.

Interestingly, DHEA supplementation in women with diminished ovarian reserve, in a carefully selected and clinician-guided context, represents the opposite application of androgen management in IVF. Modest DHEA supplementation in poor responders may improve the follicular androgen environment in a way that supports FSH receptor sensitivity and improves ovarian response.

Insulin and Metabolic Hormones

Insulin resistance, driven by excess adipose tissue, sedentary lifestyle, and genetic predisposition, elevates circulating insulin levels that disrupt reproductive hormone production and impair IVF outcomes through multiple mechanisms. Assessing fasting insulin and glucose, calculating HOMA-IR as a measure of insulin resistance, and screening for diabetes or prediabetes before IVF identifies metabolic hormonal dysregulation that can be specifically addressed.

Dietary modification targeting refined carbohydrate reduction, regular moderate exercise, and where appropriate pharmacological insulin-sensitising therapy with metformin all address insulin resistance in ways that have direct positive effects on ovarian function, egg quality, and the uterine environment for implantation.

Connecting with an experienced IVF Center in Jaipur that conducts a comprehensive hormonal workup before designing your stimulation protocol ensures that every identifiable hormonal imbalance is diagnosed and addressed before your cycle begins rather than identified retrospectively as a potential contributor to a failed attempt.

Final Thoughts

Hormonal balance is not a peripheral concern in IVF preparation. It is the biochemical foundation on which every phase of treatment rests. A complete hormonal workup before treatment begins, followed by targeted correction of identified imbalances, is one of the most clinically productive investments a couple can make before their first cycle.

For expert hormonal assessment and personalised fertility care that addresses every aspect of your endocrine profile before treatment begins, a trusted IVF Specialist in Jaipur with specific expertise in reproductive endocrinology gives your IVF journey the most complete hormonal foundation it can have.